Making $$ in the Market
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Historical Perspective@ BIEL 2009
Had to go back into my folder with BIEL to see in 2009 what was stated about the company...back then mostly a start up with great opportunities but nothing materialized...fast forward 2018 much has changed and would be interested to see what this author would write today on BIEL...holding shares for the big picture!
BIEL- Analyst Places $0.30 to $0.50 Price Target On BioElectronics (BIEL) Shares
Analyst States "Company Timing is Optimal in Light of Recent FDA Panel Recommendations to Restrict Acetaminophen and Tylenol(r) Usage"
FREDERICK, Md., Aug. 3, 2009 (GLOBE NEWSWIRE) -- BioElectronics Corporation (Pink Sheets:BIEL - News), a maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced Alquemie Partners, a strategic research and advisory boutique, has issued a new research report on the Company. The analyst, Carrie Snyder, places a target price on the shares of between $0.30 and $0.50, should expected FDA clearances be granted.
"We are very excited about BioElectronics's drug-free pain relief and healing technologies and products. With the recent FDA panel recommendation to restrict certain dosages of Tylenol(r) and acetaminophen, we believe the timing of the Company's clinical study completions and FDA filings is optimal," commented Ms. Snyder. "BioElectronics is clearly addressing a significantly sized market with its patented drug-free technologies. Should FDA clearances be given, as we expect, we believe the price of these shares could rise significantly."
A copy of the report can be downloaded at the following location: http://www.bioelectronicscorp.com/Documents/ind_analyst.pdf
About Alquemie Partners
Alquemie Partners is a strategic advisory, research and business consultancy firm where Analyst Carrie Snyder is a co-founder and partner. Prior to founding Alquemie Partners in 2008, Ms. Snyder spent over ten years in the investment banking industry at leading firms such as JPMorgan Chase, Salomon Smith Barney and Wells Fargo Securities with many years in equity research at other Wall Street firms. More information on Alquemie Partners can be viewed at www.alquemiepartners.com.
About BioElectronics Corporation
BioElectronics Corporation is the maker of ActiPatch(r) Therapy, RecoveryRx(tm) Devices, HealFast(tm) Therapy (www.healfasttherapy.com) and the Allay(tm) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see http://www.BioElectronicsCorp.com.
Tylenol is a registered trademark of McNeil Pharmaceutical, I
Todays Update @ BIEL
The goal of yesterdays meeting with the FDA was achieved as per the press release several weeks back.
The goal was to get positive feedback from the FDA which was accomplished thus they can move forward with the next step in the process with its 510K. This is a big step forward for Biel and I applaud the management team and scientist for a great job! I look forward to more positive news in the weeks, months and years ahead!
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
No luck needed just some patience - been here since 2009.
New Day @ BIEL
Congratulations to those believers in BIEL -...me since 2009!
BioElectronics Receives FDA Pre-Submission Approval for its Relief of Musculoskeletal Pain Market Clearance Application
FREDERICK, MD , May 11, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (BIEL) , www.bielcorp.com is pleased to report on the outcome of its Pre-Submission meeting on May 9th, 2018 with the US Food and Drug Administration (US FDA). The FDA’s Pre-Submission Program is designed to organize and give guidance and feedback on clinical data and what regulatory pathway should be followed to get market clearance. The focus of the May 9 pre-submission meeting was in discussing the FDA’s feedback on the clinical outcomes and statistical techniques used in reporting the back-pain study.
Upon reviewing pre-submission information on the ActiPatch® back-pain study (https://clinicaltrials.gov/ct2/show/NCT03240146), the FDA provided positive feedback on the clinical results, and guidance on a 510(k) submission to obtain expanded market clearance for over-the-counter (OTC) treatment of musculoskeletal pain. This would make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with some form of musculoskeletal pain. While ActiPatch is already FDA cleared for treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (1 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints.
The company was represented by their clinical R&D team comprising: Sree Koneru, Ph.D., VP Product Development, Ian Rawe, Director Clinical Research of BioElectronics (BIEL), Kenneth McLeod, Ph.D. Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D. Professor Duke University. Dr. Koneru, who led the discussion, expressed confidence in the FDA’s constructive feedback. “We are pleased that the FDA viewed our data and statistical methods favorably. They have provided guidance on how to combine the back-pain study results, along with our previously cleared 510(k), into a single 510(k) submission for obtaining expedited expanded market clearance.”, he said.
An additional pre-submission meeting is scheduled with the FDA on May 29th, 2018 to seek expanded indications in a separate application for OTC treatment of pain and edema following surgical procedures for its RecoveryRx® medical device.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com
Added on the dip @ BIEL
No worries juts added another 1M shares to the war chest.
Investor 100
Adding Shares @ BIEL
Been around this stock since 2009 and never has BIEL management had two meetings in the same month with the FDA thus despite the long time since that time I hold and again have added today to my position as I see a bright future down the road ( I have all the patience in the world ).
Product has relived all my shoulder and back pain too!
No luck needed just some patience.
Investor 100
Looking forward to more news @ BIEL
Been around this company since 2009 and without a doubt I have seen lots of changes with the management team and its products. The products work for me ( lower back and shoulder) thus I continue to own and add shares when possible ( 12M ). As we know Rome was not built over-night and BIEL is just getting started to a much bigger and brighter future.
https://www.marketwatch.com/story/bioelectronics-to-meet-with-fda-to-seek-expanded-otc-clearances-2018-05-02
May 9th, 2018.
The first meeting will take place on May 9th, 2018 to seek expanded indications for OTC treatment of all musculoskeletal pain for its ActiPatch(R) medical device. BioElectronics currently has OTC clearances for adjunctive treatment of two types of musculoskeletal pain: 1) Knee osteoarthritis 2) Plantar Fasciitis. Per the FDA's requirement to obtain clearance for all musculoskeletal pain, the company submitted the results of a low back pain clinical study, via a Pre-Submission in April 2018. Full details about the study can be found at the NIH's clinical trials listing page.
May 29th, 208
The second meeting will take place on May 29th, 2018 to seek expanded indications for OTC treatment of pain and edema following surgical procedures for its RecoveryRx(R) medical device. BioElectronics currently has a prescription-only clearance for the treatment of edema following blepharoplasty (eye-lid corrective surgery). The company has submitted clinical evidence to the FDA from a breast augmentation study and C-section study, via a Pre-Submission in April 2018.
https://clinicaltrials.gov/ct2/show/record/NCT03240146?term=actipatch&rank=10
Sree Koneru, Ph.D., VP of Product Development at BioElectronics
expressed confidence in the upcoming meetings and in the strength of the clinical evidence. "The clinical studies that were submitted have been conducted in an independent and rigorous manner, so we are looking forward to working with the FDA and seek their guidance to obtain expanded market clearances in a timely manner," Mr. Whelan said.
No luck needed just some patience!
Investor 100
Simpsonly at that time the whisper after the fact wasat big pharms had convinced the FDA that pills were better than patches thus BIEL did not have a chance to get approved! Today folks are sick of pills that are killing them and are using alternative measures for pain like BIEL thus the tide has turned now the FDA needs to join that sentiment in the market and BIEL management has done a good job with studies to prove their point. I think 2018-2019 is coming with big changes in the pain industry and BIEL will be one solution...I use the product for lower back and should pain from college sports injuries.
GLTA
Investor 100
Solid outline @ Biel in 2018+
Back in 2009 when I bought shares in BIEL the list of accomplishments were short with much excitement however the company stumbled on many fronts with many pumping and dumping the stock along with internal management, and product issues that thwarted any gains in sales and approvals by the FDA.
Today, as your list outlines with specifics the tide has turned and I am more confident in my investment and growth opportunity at Biel so exciting times ahead for BIEL however patience is in order thus I await since 2009 with 10M shares and counting.
Solid MOMO run this morning providing me the opportunity to buy another 2M shares...I know what I own and the opportunity at hand since 2009.
GLTA
Investor 100
Without a doubt todays " shake and bake" from MM's to rattle my cage will not work given I have been a shareholder for 10 years spoke with Andy in the early stages whose passion and conviction on this companies success has been a long process but I see the light at the end of this tunnel thus I am long and strong on BIEL with big plans! Great product on my back and shoulders.
Investor 100
BIEL & B. BRAUN
http://www.bbraunusa.com/en/change-location.html
About B. Braun Medical Ltd
B. Braun Medical Ltd is a member of the B. Braun Group, one of the world's leading healthcare companies. B. Braun manufactures and distributes on a global basis, employing more than 50,000 people worldwide.
Our global message – Sharing Expertise – clearly identifies our philosophy of the transfer of knowledge. In 175 years of development, we have acquired a wealth of knowledge that we can share with those who bear the responsibility for healthcare and associated services.
B. Braun offers healthcare professionals and hospitals an outstanding range of products, from our world renowned surgical instruments to our innovative implants and therapeutic systems, these are all matched by a comprehensive range of high quality services.
Our ability to develop innovative products, services and systems, in partnership with healthcare professionals, hospitals, universities and other specialist bodies reflects on our commitment and promise of Sharing Expertise.
For more information, please visit www.bbraun.co.uk.
B. Braun UK
This is an important development for BioElectronics. B Braun has been using RecoveryRx to improve recovery following joint replacement for many years, although in limited surgeries. However, new advances in day surgery for joint replacement have expanded our opportunity. B. Braun has recently completed a pilot program in the UK evaluating day for joint replacement. The United Kingdom’s Group day surgery program for knee and hip replacement patients and is now being implemented on a national basis. Currently there are 80,000 procedures per year involving B Braun. The “fast-track” same day hip and knee replacements are being supported by hospital physiotherapy teams visiting the patient at home and communicating using a special wireless technology tablet. Upon hospital discharge, each patient will be given an ActiPatch medical device and a prescription for 6 additional devices to help accelerate recovery and mitigate the postoperative pain. A similar program is in development for spinal surgeries.
On an international level, B. Braun’s 54,000 employees are in 60 countries and are separated into additional divisions for hospital care, surgical products, outpatient care, and home care services. It is anticipated that B. Braun’s German Group will roll out the same day hip and knee replacement program in the next few months.
https://www.prnewswire.com/news-releases/bioelectronics-announces-b-braun-as-the-uk-distributor-for-pain-device-in-orthopaedics-300020395.html
Good reason to buy and hold this stock as the PPS is moving up much higher just on this relationship alone as they move to use this product in other countries!
GLTA
Investor 100
Count me in your group as a long term shareholder since 2009 with my first purchase at .10 / 100K shares. Much different company today with a great product my family uses and has helped with shoulder and back pain! I spoke with Andy back in those early days and I knew he had the passion to get it done it was a matter of time and it looks like here we come!
GLTA
Investor 100
Good to see that Biel is moving forward.
https://www.marketwatch.com/investing/stock/biel
Bought my first 100,000 shares ten years ago at .10 to see it collapse amid rumors of poor management, stock manipulation and poor product performance. Many sold and ran for the sidelines while I held and bought more shares over the years and just forgot about them. So here we are with a great product and a management team that has risen to bring this stock back thus I am pleased to report that I have yet to sell any shares. I can attest that the product worked for me and other family members thus I believe and use the product today! Looking forward to more news this month and beyond with the share price getting back into the range I bought and then much higher.
GLTA
Investor 100
I added to my position this morning given todays news (3.5M @ .60 )..lower my cost below a $1.
GLTA
Investor 100
IPCI @ Stockcharts
This stock has taken another turn much lower today closing down 9.27% at .56 with all indicators MFI-MACD-RSI turning downward. I cannot find any updates from IPCI management thus I believe until that time the pressure to maintain these levels are difficult. I have contacted IPCI management twice during the past week with no response for any updates.
GLTA
Investor 100
Summary @IPCI CC
I had some difficulty hearing the full call given my location but what I did hear repeatedly is the company seeking partnerships to sell its products in the market as well as reduce the costs for trails. China appears to be a play to produce and distribute products but no agreement in place at this time. My conclusion is lots of products in the pipeline, 5M + in sales, and potential partnerships in 2018+.
Does IPCI management have the talent to get it done and then compete in a market-place with other companies producing the drugs at a lower cost?
GLTA
Investor 100
IPCI @ Stockcharts
Todays activity with 1.1M shares trading with it closing down 6.8% with major indicators still positive - RSI-MFI-MACD despite the dip but more importantly the news posted on CHINA is what sparked last weeks huge volume and perhaps is what Impact was anticipating ( looking for his confirmation ). I bought more shares today on todays news as I think this could be a game changer- looking for a PR from management - best news for IPCI in six months!
Investor 100
IPCI @ Stockcharts
This sleeping giant wake up yesterday with a great surge closing at .95 up 18% with over 8M shares traded. I could not find any news from IPCI management thus I am not certain what is going on but great news for those that bought in the 80's or averaged down today was a good day.
Major indicators like RSI-MACD-MFI look solid..next week?
GLTA
Investor 100
Pleased to be a shareholder despite the fact many times I thought about selling but given the facts and financial support at Mayo Clinic I remained confident better days are ahead! I think this train is just about to leave the station for 2018!
GLTA
Investor 100
Terrific news at IMUC!
Pleased to read the company came through after a long period of questions about this management team so this is a new chapter and opportunity going forward. I have held my shares since day one and will continue to add more on any dips!
Happy Holidays,
Investor 100
Thanks Impact on your update with today so meeting at team headquarters at IPCI
With a few photos of management and scientist in a facility. I like many scratching my head that
There have been so many slip ups in the past four years but as you point out they are eager to make
good of moving forward with some forms of actions to move the share price and company forward.
As we say action speaks louder than words so I will hold my judgement for another six months before selling
out completely.
Happy Holidays!
Investor 100
IPCI @ Stockcharts
Adding a chart to the conversation to the board sums it up as a state of "churning" among the low 90's as major indicators have fallen..RSI to high 30's..MACD even, MFI taken a big dip has leveled off. No question this company BOD needs some strong positive news since the ADCOM disaster but perhaps like many on this board I have contacted the company for answers and received nothing in return. Took a small loss having cut my holdings 50% and will hold on til early 2018 and then move on with other plays like ONCS that took off this week and has more juice ( Doog )IMHO!
Happy Holidays to all.
Investor 100
IPCI @ Stockcharts
From all key indicators..RSI..MACD..MFI and having closed passed the 50MA yesterday we look ready for the next climb to the 200MA. Yesterday open at $1.08 closing at $1.11 ( high $1.25 or 13%) with volume at 1.6M shares trading. Next news for the stock is Q3 reporting. Holding shares.
Investor 100
IPCI ( Update ) @ Stockcharts
Solid chart progession at IPCI with almost 900K shares trading, open at $1.08 as high as $1.25..moved past 50MA with the 200 MA at $2.05 or .80..indicators moving higher..13% gain today alone ....any positive news at IPCi takes us much higher...holding shares.
Investor 100
No doubt doog that 50MA is on the horizon...moving higher faster than anticipated....Choo..Choo
Investor 100
Beast @ IMNP
No Press Release on any news however volume and price up huge!
Rumored in the past have included partnerships so we shall see.
Investor 100
IPCI @ Stockcharts
The backlash of last weeks Adcom continues to put pressure on this stock causing one to flee the scene, sit idle intil the next shoe drops ( earnings, ATM, study costs updates) or buy the dip. I happen to again add a few more shares to my pile anticipating that in 6-18 months we will have much better results and a higher PPS! This drug crisis is not going away any time soon and perhaps is going to get worse! Holding 110K shares.
The only indicator that looks like a curl upward is RSI...bottoms up!
White House opioid commission urges Trump to declare federal state of emergency
Opioid deaths have risen sharply for years and could kill nearly half a million people in the U.S. over the next decade if not addressed, according to a recent study from Stat News.
http://thehill.com/business-a-lobbying/344674-white-house-opioid-commission-urges-trump-to-declare-federal-state-of
Investor 100
IPCI @ Stockcharts
Not quite the same chart in weeks past given last weeks news however one can look at it and say " glass half empty or half full " and given that this stock is not a one trick pony of goods in its portfolio then it does live another day with opportunities. I happen to believe it lives another day and doubled my position from 50K- 100K with a long term outlook.
Investor 100
Folks playing the pump and dump game with nothing else but rumors of a buyout that is baseless!
Update@IMUC
As they say "no news is good news" not the case for the folks
buying in the 2's yesterday. volume all but dried up and buy- out
also put to rest with nothing yet PR from the company-!
Investor 100